* Scios Inc., of Mountain View, Calif., and its partner, Wyeth-Ayerst, of Radnor, Pa., began a Phase II trial of the former's Fiblast trafermin for treatment of peripheral vascular disease patients suffering from pain when they exercise. The drug, a form of human basic fibroblast growth factor, demonstrated in animal studies it could improve blood flow to ischemic areas. Wyeth-Ayerst is a pharmaceutical division of American Home Products Corp., of Madison, N.J.
* VIMRx Pharmaceuticals Inc., of Wilmington, Del., completed its acquisition of a 68 percent stake in Innovir Laboratories Inc., of New York. VIMRx purchased 9.5 million Innovir shares from The Aries Funds, a Cayman Island Trust, for 3 million VIMRx shares and $3 million in cash.